Malignant melanoma is the most lethal form of skin cancer and accounts for almost 80% of skin cancer deaths. About 60% of melanomas have a mutation in the BRAF oncogene at V600E. The FDA recently approved (January 2014) the combination of a BRAF inhibitor (Dabrafenib) and a MEK 1/2 inhibitor (Trametinib) to treat this type of melanoma. A problem with this therapy has been the development of cell resistance and and back acquired resistance in many patients.
This research has determined that Mcl-1 is over expressed with the treatment of both BRaf Inhibitors and/or MEK 1/2 inhibitors. The addition of a Mcl-1 inhibitor to the combination therapy prevents cells from becoming resistant to treatment and will also revert back acquired resistance. This invention provides a novel drug combination which would not only overcome BRAF inhibitor resistance but also improve overall treatment of late stage malignant melanoma.
This invention will fit into the market as a melanoma treatment. The primary customer will likely be doctors and medical facilities. The end users will be patients. This technology will be distributed across the market according to application and demand, mainly across the seven main markets (the U.S., France, Germany, Italy, Spain, the UK, and Japan).
Features, Benefits, & Advantages:
• Preventing resistance to BRAF and MEK inhibitors
• Reverting resistance in cancer cells
• May prevent resistance for any inhibitor that targets the MAPK pathway